GEN-MKT-18-7897-A
Mar 2, 2017 | Blogs, Food / Beverage | 0 comments
As we settle into 2017, I can’t help but reflect on the previous year’s food safety. Take for example the legislative changes meant to contain contamination outbreaks like those happening in places like China, Singapore, and New Zealand. Over the past year, we have developed new methods that detect antibiotics in poultry feed, LC-MS/MS Analysis of Emerging Contaminants, and help set food standards in China. All the while developing more sophisticated technology to keep up with testing demands.
Changes like this do not come easy. At SCIEX, one must be on top of trends before they happen, and as such, our R&D department spent most of the year investing in this new vision and updating mass spectrometry instruments to meet the challenges of today’s food labs.
You can read more about mine and my colleague’s perspectives on emerging technologies in Asian Food Journal, in which we not only discuss product innovation and highlights but trends and opportunities too. Meanwhile, keep a look out for monthly blogs keeping you up to date on continuous trends.
The Take Away: Labs around the world are starting to migrate to High-Resolution MS workflows, particularly SWATH® Acquisition. Join me in adding your thoughts on what food and safety trends are coming this year by commenting below.
For research use only. Not for use in diagnostic procedures.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network